{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:46:28Z","timestamp":1792086388037,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Science and Technology Commission of Shanghai Municipality, China","award":["14DZ1940803"],"award-info":[{"award-number":["14DZ1940803"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1804251"],"award-info":[{"award-number":["U1804251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"medical-engineering cross fund of Shanghai Jiao Tong University","award":["YG2019ZDA02"],"award-info":[{"award-number":["YG2019ZDA02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although the drug-eluting stent (DES) has become the standard for percutaneous coronary intervention (PCI)-based revascularization, concerns remain regarding the use of DES, mainly due to its permanent rigid constraint to vessels. A drug-eluting bioresorbable stent (BRS) was thus developed as an alternative to DES, which can be absorbed entirely after its therapeutic period. Magnesium (Mg)-based BRSs have attracted a great deal of attention due to their suitable mechanical properties, innovative chemical features, and well-proven biocompatibility. However, the primary disadvantage of Mg-based BRSs is the rapid degradation rate, resulting in the early loss of structural support long before the recovery of vascular function. Recently, a new type of patented Mg\u2013Nd\u2013Zn-Zr alloy (JDBM) was developed at Shanghai Jiao Tong University to reduce the degradation rate compared to commercial Mg alloys. In the present investigation, a poly(\n                    <jats:sc>d<\/jats:sc>\n                    ,\n                    <jats:sc>l<\/jats:sc>\n                    -lactic acid)-coated and rapamycin eluting (PDLLA\/RAPA) JDBM BRS was prepared, and its biosafety and efficacy for coronary artery stenosis were evaluated via in vitro and in vivo experiments. The degree of smooth muscle cell adhesion to the PDLLA\/RAPA coated alloy and the rapamycin pharmacokinetics of JDBM BRS were first assessed in vitro. JDBM BRS and commercial DES FIREHAWK were then implanted in the coronary arteries of a porcine model. Neointimal hyperplasia was evaluated at 30, 90, and 180\u00a0days, and re-endothelialization was evaluated at 30\u00a0days. Furthermore, Micro-CT and optical coherence tomography (OCT) analyses were performed 180\u00a0days after stent implantation to evaluate the technical feasibility, biocompatibility, and degradation characteristics of JDBM BRS in vivo. The results show the ability of a PDLLA\/RAPA coated JDBM to inhibit smooth muscle cell adhesion and moderate the drug release rate of JDBM BRS in vitro. In vivo, low local and systemic risks of JDBM BRS were demonstrated in the porcine model, with preserved mechanical integrity after 6\u00a0months of implantation. We also showed that this novel BRS was associated with a similar efficacy profile compared with standard DES and high anti-restenosis performance. These findings may confer long term advantages for using this BRS over a traditional DES.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-86803-0","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T06:03:08Z","timestamp":1617256988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Biosafety and efficacy evaluation of a biodegradable magnesium-based drug-eluting stent in porcine coronary artery"],"prefix":"10.1038","volume":"11","author":[{"given":"Jinzhou","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daopeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"86803_CR1","doi-asserted-by":"publisher","first-page":"e002230","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","volume":"8","author":"J Iqbal","year":"2015","unstructured":"Iqbal, J. et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: Final 5-year report of the RESOLUTE all-comers trial. Circ. Cardiovasc. Interv. 8, e002230 (2015).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"86803_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ejcts\/ezy289","volume":"55","author":"M Sousa-Uva","year":"2019","unstructured":"Sousa-Uva, M. et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur. J. Cardio-thorac. Surg. 55, 4\u201390 (2019).","journal-title":"Eur. J. Cardio-thorac. Surg."},{"key":"86803_CR3","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.693739","volume":"115","author":"AV Finn","year":"2007","unstructured":"Finn, A. V. et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 115, 2435\u20132441 (2007).","journal-title":"Circulation"},{"key":"86803_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.109.854398","volume":"120","author":"S Cook","year":"2009","unstructured":"Cook, S. et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120, 391\u2013399 (2009).","journal-title":"Circulation"},{"key":"86803_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","volume":"48","author":"M Joner","year":"2006","unstructured":"Joner, M. et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193\u2013202 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86803_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","volume":"109","author":"R Virmani","year":"2004","unstructured":"Virmani, R. et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious?. Circulation 109, 701\u2013705 (2004).","journal-title":"Circulation"},{"key":"86803_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","volume":"369","author":"J Daemen","year":"2007","unstructured":"Daemen, J. et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369, 667\u2013678 (2007).","journal-title":"Lancet"},{"key":"86803_CR8","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.jacc.2008.07.006","volume":"52","author":"P Wenaweser","year":"2008","unstructured":"Wenaweser, P. et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52, 1134\u20131140 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86803_CR9","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.09.041","volume":"64","author":"J Wiebe","year":"2014","unstructured":"Wiebe, J., Nef, H. M. & Hamm, C. W. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J. Am. Coll. Cardiol. 64, 2541\u20132551 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86803_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/eurheartj\/eht542","volume":"35","author":"J Iqbal","year":"2014","unstructured":"Iqbal, J. et al. Bioresorbable scaffolds: Rationale, current status, challenges, and future. Eur. Heart J. 35, 765\u2013776 (2014).","journal-title":"Eur. Heart J."},{"key":"86803_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.110.971606","volume":"123","author":"Y Onuma","year":"2011","unstructured":"Onuma, Y. & Serruys, P. W. Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization?. Circulation 123, 779\u2013797 (2011).","journal-title":"Circulation"},{"key":"86803_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ccd.20895","volume":"69","author":"JA Ormiston","year":"2007","unstructured":"Ormiston, J. A., Webster, M. W. & Armstrong, G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: The BVS poly-l-lactic acid everolimus-eluting coronary stent. Catheterization Cardiovasc. Interv. 69, 128\u2013131 (2007).","journal-title":"Catheterization Cardiovasc. Interv."},{"key":"86803_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/eurheartj\/ehr384","volume":"33","author":"PW Serruys","year":"2012","unstructured":"Serruys, P. W., Garcia-Garcia, H. M. & Onuma, Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade?. Eur. Heart J. 33, 16\u201325b (2012).","journal-title":"Eur. Heart J."},{"key":"86803_CR14","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.jacc.2017.04.011","volume":"69","author":"S Sorrentino","year":"2017","unstructured":"Sorrentino, S. et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. J. Am. Coll. Cardiol. 69, 3055\u20133066 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86803_CR15","doi-asserted-by":"publisher","first-page":"S903","DOI":"10.21037\/jtd.2017.06.34","volume":"9","author":"C Rapetto","year":"2017","unstructured":"Rapetto, C. & Leoncini, M. Magmaris: A new generation metallic sirolimus-eluting fully bioresorbable scaffold: Present status and future perspectives. J. Thorac. Dis. 9, S903\u2013S913 (2017).","journal-title":"J. Thorac. Dis."},{"key":"86803_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/heart.89.6.651","volume":"89","author":"B Heublein","year":"2003","unstructured":"Heublein, B. et al. Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology?. Heart 89, 651\u2013656 (2003).","journal-title":"Heart"},{"key":"86803_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jmbbm.2012.02.002","volume":"9","author":"X Zhang","year":"2012","unstructured":"Zhang, X., Yuan, G., Niu, J., Fu, P. & Ding, W. Microstructure, mechanical properties, biocorrosion behavior, and cytotoxicity of as-extruded Mg-Nd-Zn-Zr alloy with different extrusion ratios. J. Mech. Behav. Biomed. Mater. 9, 153\u2013162 (2012).","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"86803_CR18","doi-asserted-by":"publisher","first-page":"9517","DOI":"10.1039\/c3nr02912c","volume":"5","author":"L Mao","year":"2013","unstructured":"Mao, L. et al. Nanophasic biodegradation enhances the durability and biocompatibility of magnesium alloys for the next-generation vascular stents. Nanoscale 5, 9517\u20139522 (2013).","journal-title":"Nanoscale"},{"key":"86803_CR19","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.actbio.2009.09.024","volume":"6","author":"F Feyerabend","year":"2010","unstructured":"Feyerabend, F. et al. Evaluation of short-term effects of rare earth and other elements used in magnesium alloys on primary cells and cell lines. Acta Biomater. 6, 1834\u20131842 (2010).","journal-title":"Acta Biomater."},{"key":"86803_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jmbbm.2011.05.026","volume":"7","author":"X Zhang","year":"2012","unstructured":"Zhang, X. et al. Effects of extrusion and heat treatment on the mechanical properties and biocorrosion behaviors of a Mg-Nd-Zn-Zr alloy. J. Mech. Behav. Biomed. Mater. 7, 77\u201386 (2012).","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"86803_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.corsci.2017.04.016","volume":"123","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. Understanding the effect of magnesium degradation on drug release and anti-proliferation on smooth muscle cells for magnesium-based drug eluting stents. Corros. Sci. 123, 297\u2013309 (2017).","journal-title":"Corros. Sci."},{"key":"86803_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.msec.2014.12.024","volume":"48","author":"F Liu","year":"2015","unstructured":"Liu, F., Chen, C., Niu, J., Pei, J. & Yuan, G. The processing of Mg alloy micro-tubes for biodegradable vascular stents. Materials Sci. Eng. C. 48, 400\u2013407 (2015).","journal-title":"Materials Sci. Eng. C."},{"key":"86803_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msec.2017.05.124","volume":"80","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. In vitro and in vivo degradation of rapamycin-eluting Mg-Nd-Zn-Zr alloy stents in porcine coronary arteries. Mater. Eng. C Mater. Biol. Appl. 80, 1\u20136 (2017).","journal-title":"Mater. Eng. C Mater. Biol. Appl."},{"key":"86803_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s10856-017-5864-0","volume":"28","author":"J Zhu","year":"2017","unstructured":"Zhu, J. et al. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent. J. Mater. Sci. Mater. Med. 28, 54 (2017).","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"86803_CR25","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1016\/j.biomaterials.2012.07.066","volume":"33","author":"JZ Zhu","year":"2012","unstructured":"Zhu, J. Z. et al. Hemocompatibility of drug-eluting coronary stents coated with sulfonated poly (styrene-block-isobutylene-block-styrene). Biomaterials 33, 8204\u20138212 (2012).","journal-title":"Biomaterials"},{"key":"86803_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s12325-020-01273-6","volume":"37","author":"Z Zhu","year":"2020","unstructured":"Zhu, Z. et al. Efficacy of zotarolimus-eluting stents in treating diabetic coronary lesions: An optical coherence tomography study. Adv. Ther. 37, 1579\u20131590 (2020).","journal-title":"Adv. Ther."},{"key":"86803_CR27","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jcin.2019.05.001","volume":"12","author":"B Xu","year":"2019","unstructured":"Xu, B. et al. 2-Year clinical outcomes of an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent compared with a durable-polymer everolimus-eluting stent. JACC Cardiovasc. Interv. 12, 1679\u20131687 (2019).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ahj.2011.10.016","volume":"163","author":"JS Kim","year":"2012","unstructured":"Kim, J. S. et al. ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am. Heart J. 163, 601\u2013607 (2012).","journal-title":"Am. Heart J."},{"key":"86803_CR29","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jcin.2015.02.020","volume":"8","author":"L Gao","year":"2015","unstructured":"Gao, L. et al. Comparison of neoatherosclerosis and neovascularization between patients with and without diabetes: An optical coherence tomography study. JACC Cardiovasc. Interv. 8, 1044\u20131052 (2015).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.amjcard.2006.01.031","volume":"97","author":"T Kume","year":"2006","unstructured":"Kume, T. et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am. J. Cardiol. 97, 1713\u20131717 (2006).","journal-title":"Am. J. Cardiol."},{"key":"86803_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/BME-151551","volume":"26","author":"Z Zhu","year":"2015","unstructured":"Zhu, Z. et al. Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Bio-Med. Mater. Eng. 26, 79\u201388 (2015).","journal-title":"Bio-Med. Mater. Eng."},{"key":"86803_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jcin.2013.07.007","volume":"7","author":"S Verheye","year":"2014","unstructured":"Verheye, S. et al. A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv. 7, 89\u201399 (2014).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR33","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.4244\/EIJV10I12A243","volume":"10","author":"A Abizaid","year":"2015","unstructured":"Abizaid, A. et al. The ABSORB EXTEND study: Preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 10, 1396\u20131401 (2015).","journal-title":"EuroIntervention"},{"key":"86803_CR34","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","volume":"373","author":"SG Ellis","year":"2015","unstructured":"Ellis, S. G. et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N. Engl. J. Med. 373, 1905\u20131915 (2015).","journal-title":"N. Engl. J. Med."},{"key":"86803_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"PW Serruys","year":"2015","unstructured":"Serruys, P. W. et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 385, 43\u201354 (2015).","journal-title":"Lancet"},{"key":"86803_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jcin.2015.12.004","volume":"9","author":"A Abizaid","year":"2016","unstructured":"Abizaid, A. et al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc. Interv. 9, 565\u2013574 (2016).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)00447-X","volume":"387","author":"M Haude","year":"2016","unstructured":"Haude, M. et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet 387, 31\u201339 (2016).","journal-title":"Lancet"},{"key":"86803_CR38","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","volume":"371","author":"JA Ormiston","year":"2008","unstructured":"Ormiston, J. A. et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 371, 899\u2013907 (2008).","journal-title":"Lancet"},{"key":"86803_CR39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","volume":"67","author":"S Puricel","year":"2016","unstructured":"Puricel, S. et al. Bioresorbable coronary scaffold thrombosis: Multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J. Am. Coll. Cardiol. 67, 921\u2013931 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"86803_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.carrev.2014.01.011","volume":"15","author":"H Kitabata","year":"2014","unstructured":"Kitabata, H., Waksman, R. & Warnack, B. Bioresorbable metal scaffold for cardiovascular application: Current knowledge and future perspectives. Cardiovasc. Revascularization Med. 15, 109\u2013116 (2014).","journal-title":"Cardiovasc. Revascularization Med."},{"key":"86803_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jcin.2011.04.009","volume":"4","author":"J Gomez-Lara","year":"2011","unstructured":"Gomez-Lara, J. et al. Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-up. JACC Cardiovasc. Interv. 4, 789\u2013799 (2011).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR42","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.jcin.2017.07.033","volume":"10","author":"A Abizaid","year":"2017","unstructured":"Abizaid, A. et al. 6-month clinical and angiographic outcomes of a novel radiopaque sirolimus-eluting bioresorbable vascular scaffold: The FANTOM II study. JACC Cardiovasc. Interv. 10, 1832\u20131838 (2017).","journal-title":"JACC Cardiovasc. Interv."},{"key":"86803_CR43","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ccd.20727","volume":"68","author":"R Waksman","year":"2006","unstructured":"Waksman, R. et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheterization Cardiovasc. Interv 68, 607\u2013617 (2006) (discussion 18\u20139).","journal-title":"Catheterization Cardiovasc. Interv"},{"key":"86803_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0167-5273(86)90239-1","volume":"12","author":"LF Smith","year":"1986","unstructured":"Smith, L. F., Heagerty, A. M., Bing, R. F. & Barnett, D. B. Intravenous infusion of magnesium sulphate after acute myocardial infarction: Effects on arrhythmias and mortality. Int. J. Cardiol. 12, 175\u2013183 (1986).","journal-title":"Int. J. Cardiol."},{"key":"86803_CR45","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1161\/hq0901.094493","volume":"21","author":"V Rukshin","year":"2001","unstructured":"Rukshin, V. et al. Intravenous magnesium in experimental stent thrombosis in swine. Arterioscler. Thromb. Vasc. Biol. 21, 1544\u20131549 (2001).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"86803_CR46","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1161\/01.CIR.0000014612.88433.62","volume":"105","author":"V Rukshin","year":"2002","unstructured":"Rukshin, V. et al. Comparative antithrombotic effects of magnesium sulfate and the platelet glycoprotein IIb\/IIIa inhibitors tirofiban and eptifibatide in a canine model of stent thrombosis. Circulation 105, 1970\u20131975 (2002).","journal-title":"Circulation"},{"key":"86803_CR47","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1161\/01.CIR.92.9.2617","volume":"92","author":"CW Christensen","year":"1995","unstructured":"Christensen, C. W., Rieder, M. A., Silverstein, E. L. & Gencheff, N. E. Magnesium sulfate reduces myocardial infarct size when administered before but not after coronary reperfusion in a canine model. Circulation 92, 2617\u20132621 (1995).","journal-title":"Circulation"},{"key":"86803_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/sj.bjp.0702342","volume":"126","author":"PA Kemp","year":"1999","unstructured":"Kemp, P. A., Gardiner, S. M., March, J. E., Rubin, P. C. & Bennett, T. Assessment of the effects of endothelin-1 and magnesium sulphate on regional blood flows in conscious rats, by the coloured microsphere reference technique. Br. J. Pharmacol. 126, 621\u2013626 (1999).","journal-title":"Br. J. Pharmacol."},{"key":"86803_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00005344-200307000-00004","volume":"42","author":"N Berthon","year":"2003","unstructured":"Berthon, N., Laurant, P., Fellmann, D. & Berthelot, A. Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats. J. Cardiovasc. Pharmacol. 42, 24\u201331 (2003).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"86803_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jbm.b.31918","volume":"100","author":"K Sternberg","year":"2012","unstructured":"Sternberg, K. et al. Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. J. Biomed. Mater. Res. B Appl. Biomater. 100, 41\u201350 (2012).","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"86803_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mser.2014.01.001","volume":"77","author":"YF Zheng","year":"2014","unstructured":"Zheng, Y. F., Gu, X. N. & Witte, F. Biodegradable metals. Mater. Sci. Eng. R Rep. Rev. J. 77, 1\u201334 (2014).","journal-title":"Mater. Sci. Eng. R Rep. Rev. J."},{"key":"86803_CR52","doi-asserted-by":"publisher","first-page":"24492","DOI":"10.3390\/ijms141224492","volume":"14","author":"CM Campos","year":"2013","unstructured":"Campos, C. M. et al. Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. Int. J. Mol. Sci. 14, 24492\u201324500 (2013).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86803-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:10:01Z","timestamp":1675062601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86803"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86803-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-110813\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7330"}}